**SUPPLEMENTARY MATERIAL**

**Table S1.** Assessment of disease progression—proportions of patients experiencing ≥10% decline in FVC or death, ≥50-m decline in 6MWD or death and ≥20-point worsening of UCSD SOBQ score or death in the pooled placebo population stratified by baseline FVC (≥80% and <80% predicted) or baseline GAP index stage (GAP I and GAP II–III) at 12 months

| Outcome at 12 Months | Baseline FVC ≥80% | Baseline FVC <80% | Baseline GAP Stage I | Baseline GAP Stage II-III |
|---|---|---|---|---|
| Pooled placebo population, n | 170 | 454 | 235 | 387 |
| FVC, % of patients | | | | |
| ≥10% decline or death | 21.8 | 28.0 | 21.7 | 28.9 |
| No decline | 21.2 | 16.3 | 20.4 | 15.8 |
| 6MWD, % of patients | | | | |
| ≥50-m decline or death | 24.1 | 38.8 | 26.6 | 39.7 |
| No decline | 37.3 | 33.4 | 37.3 | 32.9 |
| UCSD SOBQ, % of patients | | | | |
| ≥20-point change in UCSD SOBQ score or death | 18.0 | 36.4 | 21.4 | 37.5 |
| No decline | 37.1 | 24.9 | 36.8 | 23.1 |

6MWD: 6-minute walk distance; FVC: forced vital capacity; UCSD SOBQ: University of California—San Diego Shortness of Breath Questionnaire.

**Table S2.** Proportions of patients experiencing ≥10% decline in FVC or death, ≥50-m decline in 6MWD or death and ≥20-point worsening of UCSD SOBQ score or death in the pooled pirfenidone population stratified by baseline FVC (≥80% and <80% predicted) or baseline GAP index stage (GAP I and GAP II–III) at 12 months

| Outcome at 12 Months | Baseline FVC ≥80% | Baseline FVC <80% | Baseline GAP Stage I | Baseline GAP Stage II-III |
|---|---|---|---|---|
| Pooled pirfenidone population, n | 146 | 477 | 247 | 376 |
| FVC, % of patients | | | | |
| ≥10% decline or death | 14.4 | 14.9 | 13.4 | 15.7 |
| No decline | 37.7 | 25.2 | 31.2 | 26.1 |
| 6MWD, % of patients | | | | |
| ≥50-m decline or death | 16.8 | 27.2 | 19.7 | 28.2 |
| No decline | 46.2 | 39.0 | 47.5 | 36.2 |
| UCSD SOBQ, % of patients | | | | |
| ≥20-point change in UCSD SOBQ score or death | 18.1 | 25.8 | 17.4 | 28.3 |
| No decline | 40.3 | 27.9 | 35.5 | 27.7 |

6MWD, 6-minute walk distance; FVC, forced vital capacity; UCSD SOBQ, University of California—San Diego Shortness of Breath Questionnaire.

**Table S3.** Linear change in FVC (percent predicted and L) without imputation through 12 months by treatment group and baseline FVC and GAP index stage

| Slope (Year)* | Pirfenidone 2403 mg/day (N=477) | Placebo (N=454) | Mean Difference† | Relative Difference, %‡ | *P* Value§ |
|---|---|---|---|---|---|
| FVC, % predicted | | | | | |
| Baseline FVC ≥80% | −1.92 | −5.19 | 3.269 | 63.0 | <0.0001 |
| Baseline FVC <80% | −3.66 | −5.95 | 2.290 | 38.5 | <0.0001 |
| Baseline GAP Stage I | −2.93 | −5.78 | 2.847 | 49.3 | <0.0001 |
| Baseline GAP Stage II-III | −3.41 | −5.67 | 2.262 | 39.9 | <0.0001 |
| FVC, L | | | | | |
| Baseline FVC ≥80% | −0.083 | −0.187 | 0.1047 | 55.9 | 0.0010 |
| Baseline FVC <80% | −0.149 | −0.238 | 0.0891 | 37.5 | <0.0001 |
| Baseline GAP Stage I | −0.120 | −0.215 | 0.0945 | 44.0 | 0.0002 |
| Baseline GAP Stage II-III | −0.140 | −0.226 | 0.0853 | 37.8 | <0.0001 |

FVC, forced vital capacity.

*Change from baseline was calculated as the12-month value minus the baseline value.

†Difference in mean: (pirfenidone − placebo).

‡Relative difference in mean: 100*(pirfenidone − placebo)/(|placebo|).

§Calculated from the mixed linear model comparing pirfenidone 2403 mg/day to placebo, with change as the outcome variable; study (PIPF-004, PIPF-006 and PIPF-016), geographic region (United States and the rest of the world) within study and assessment time by treatment as fixed effects; baseline as a covariate; subject and subject by assessment time as random effects with variance components covariance structure.